TREATMENT RESEARCH IN CANCER NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


TREATMENT RESEARCH IN CANCER

Cancer Growth Prog; 1:162-70 1989. Unique Identifier : AIDSLINE ICDB/90657733
Curt GA; Chabner BA; NCI, Bethesda, MD 20892

Abstract: Considerable advances have been made against several types of cancer, with large improvements in long-term survival for acute lymphocytic leukemia, Hodgkin's disease, diffuse lymphoma, testicular cancer, choriocarcinoma, childhood sarcomas, postmenopausal Stage II breast cancer, and small cell lung cancer (limited stage). Despite this, numerous patients in the United States do not receive the best treatment available. The NCI has initiated several programs to transfer treatment research advances to the community (eg, Physician Data Query Computer Data Base, Cooperative Group Outreach Programs, and Office of Communications Cancer 'Hot Line'). Preclinical and clinical research activities sponsored by NCI are reviewed, including drug development (application of the advances in tumor biology); new drug screening programs; AIDS drug development; studies of growth factor antagonists, metastasis blockers, tumor necrosis factor, and immune stimulation therapy/adoptive immunotherapy; and advances in diagnostic imaging and radiation therapy. NCI-supported clinical treatment trials are bringing the advances in basic cancer biology into the arena of clinical cancer medicine. Over 5000 physicians engaged in NCI studies follow 75,000 patients annually and see an additional 200,000 patients with cancer each year. The NCI is unique within NIH both in developing new anticancer drugs using the contract mechanism and in its support of a nationwide network of cancer centers, outreach programs, community clinical oncology programs, and cooperative groups for clinical trials. (35 Refs)
Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY Antineoplastic Agents/THERAPEUTIC USE Biological Products/THERAPEUTIC USE Cell Division/DRUG EFFECTS Clinical Trials Comparative Study Drug Screening Assays, Antitumor Human Immunotherapy Neoplasm Metastasis Neoplasms/DRUG THERAPY/MORTALITY/RADIOTHERAPY/*THERAPY CLINICAL TRIAL JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
900228
M9020585

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .